The big names on the board are just that: experienced players in the game: just remember that as a little investor, you're just a ball to be kicked around when the play calls for it.
Cap raising is a big concern for me here, because their revenue stream is modest and their ambitions are big, and that board has no qualms about diluting for the benefit of the big end of town.
That being said, I am actually accumulating. I think the upside is worth the risk of getting kicked around by the board.
What I'm holding out for is a clinical validation and commercialisation of the (from the BioMed days) of the surgical patch. That however is still some time off.
